| Ytd | -53.45% | |
| 1y | -82.47% |
| Open | 1.08 | Prev Close | 1.12 | Low | 1.08 | High | 1.11 | Mkt Cap | 736.08K |
| Vol | 0.00 | Avg Vol | 70.79K | EPS | -5.31 | P/E | -0.20 | Forward P/E | -0.32 |
| Beta | 0.79 | Short Ratio | 0.52 | Inst. Own | 0.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.25 | 200-d Avg | 1.79 | 1yr Est | 6.00 |
DRMA News
- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, e
- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch,
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - D
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skinca
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Fr
Planet Labs (PL) stock rose in pre-market trading after better-than-expected Q4 sales and strong FY2
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEG
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) is expected to issue its results before the ma
-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combin
U.S. stock futures swung between gains and losses on Tuesday after Monday's declines. Futures of maj
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds up
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds up
SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combinatio
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XY
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences V
SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasd
- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne R
